Baidu
map

中国癌症相关性疲乏临床实践诊疗指南 (2021年版)

2021-09-30 中华医学会肿瘤学分会肿瘤支持康复治疗学组 中国癌症杂志

癌症已成为严重威胁中国人群健康的主要公共卫生问题之一。研究发现,癌症与疲乏关系密切,癌症相关性疲 乏是癌症患者最为常见的伴随症状。

中文标题:

中国癌症相关性疲乏临床实践诊疗指南 (2021年版)

发布日期:

2021-09-30

简要介绍:

癌症已成为严重威胁中国人群健康的主要公共卫生问题之一。研究发现,癌症与疲乏关系密切,癌症相关性疲 乏是癌症患者最为常见的伴随症状。癌症相关性疲乏严重影响癌症患者的工作、社会关系、情绪、日常活动和生活质量, 可导致部分患者治疗中断,甚至影响癌症患者的生存时间。但目前中国尚无相关的指南可用于指导癌症相关性疲乏的临床 诊治,中华医学会肿瘤学分会肿瘤支持康复治疗学组专家对癌症相关性疲乏的研究进展进行归纳总结,旨在及时传递重要 信息,指导临床实践。本指南主要涵盖癌症相关性疲乏的定义、流行病学、临床表现、发病机制、影响因素、中医证候类 型、筛查、临床评估及中西医结合治疗等方面,为癌症相关性疲乏临床诊疗提供参考依据,将有助于临床医师对癌症相关 性疲乏患者进行规范化治疗,改善中国癌症相关性疲乏患者的临床结局。

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1248084, encodeId=1db9124808438, content=附件下载失败, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac8124994, createdName=ms7000000050646543, createdTime=Fri Sep 09 11:31:42 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242301, encodeId=c6131242301e7, content=💪🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88af8257004, createdName=ms7000000469747248, createdTime=Wed Aug 31 16:41:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075295, encodeId=fb9110e52959c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:03:14 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-09-09 ms7000000050646543

    附件下载失败

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1248084, encodeId=1db9124808438, content=附件下载失败, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac8124994, createdName=ms7000000050646543, createdTime=Fri Sep 09 11:31:42 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242301, encodeId=c6131242301e7, content=💪🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88af8257004, createdName=ms7000000469747248, createdTime=Wed Aug 31 16:41:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075295, encodeId=fb9110e52959c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:03:14 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-08-31 ms7000000469747248

    💪🏻

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1248084, encodeId=1db9124808438, content=附件下载失败, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbac8124994, createdName=ms7000000050646543, createdTime=Fri Sep 09 11:31:42 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242301, encodeId=c6131242301e7, content=💪🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88af8257004, createdName=ms7000000469747248, createdTime=Wed Aug 31 16:41:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075295, encodeId=fb9110e52959c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:03:14 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 微探

    学习学习

    0

拓展阅读

2014年ASCO 美国成人癌症幸存者疲劳的筛查和管理指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2014-04-14

2014 ASE/EACI专家共识:多峰性成像技术评估成人患者癌症治疗期间及之后

美国超声心动图学会(ASE,American Society of Echocardiography) · 2014-07-12

2014 COSA立场声明:癌症患者补充和替代疗法的应用

澳大利亚临床肿瘤学会(COSA,Clinical Oncology Society of Australia) · 2014-09-22

2014 ASCO官方声明:一期试验在 研究和治疗中的重要作用

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2014-12-15

2015 ISTH指南:癌症相关的弥散性血管内凝血的管理

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2015-01-05

2014 ASCO 癌症患者静脉血栓栓塞防治指南(更新版)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2015-01-20

Baidu
map
Baidu
map
Baidu
map